



Unmet Clinical Need: effectively treating periprosthetic infection



- Patient's **lifetime risk** of total joint infection: early/acute, delayed/chronic or late/blood borne.
- Periprosthetic Joint Infection is the **leading cause** for early arthroplasty revision surgeries
- Following 2-Stage Revision (SOC), 5 yr **survival rate is below** prostate and breast cancer rates.⁶
- Current treatment options: **poor success range: 50-90%; high cost range: \$ 49k-163k/patient**^{7,8}



Key Reason: Non-targeted antibiotic dosing results in subtherapeutic levels

Existing antibiotics work against joint infection bacteria if exposed to sufficient concentration over time. Persistent infection can be enabled by SOC (Standard of Care) due to limited/lower concentrations at site of infection. Meanwhile, subtherapeutic systemic exposure is increasing risk of developing antibiotic resistance.

Infesting bacterial biofilms attach to implant and tissue. Eradication can be achieved via thorough debridement & therapeutic antibiotic concentration at site held over time.

- SOC systemic IV antibiotics: can't achieve biofilm therapeutic levels in synovial fluid⁹
- SOC temp. antibiotic-impregnated eluting spacers can't maintain levels in synovial fluid over time¹⁰
- In published research, 6 weeks of daily intraarticular injections produced therapeutic antibiotic concentrations **resulting in better patient outcomes than SOC**¹¹

By 2024:


3.4M / yr Total US Primary Joints (hips & knees);
 12.6M Americans with Total Joint Implants;
 Est: 141k / yr US Total Joint Infections^{1,2,3}

\$1B US Market


Our Approach: local delivery of antibiotic in the joint to maintain therapeutic levels

Externally-controlled Intraarticular Drug Delivery

1. **Implanted, Refillable Antibiotic Reservoir**
2. **Adjustable, Consistent Antibiotic Dosing**
3. **Range of Antibiotics & Solutions***
4. **Durability / Performance / Permanent**
5. **Procedure & Joint Implant Compatibility**
6. **Non-electronic Implanted System**
7. **Resident, No Skin Penetration**



Replacement Spacer for TKA



Remote Drug Delivery for THA

Better Treatment: for implant retention, lower cost & reduced morbidity

We: * understand the combination product regulatory pathway; * have foundational intellectual property (2 issued patents); * with ongoing strategic interest; * an advisory board of renowned surgeons and clinicians; * under strong leadership and support; * broad technology applicability. For additional information, please contact us.

Better outcomes can expand **Implant Retention** cases; NEJM estimates 60% of PJI patients are viable candidates for I&D¹²

Potential Savings of \$96,500 per patient over current 2-stage SOC

Jeff Castleberry, CEO, President & Co-Founder
ForCast Orthopedics jcastleberry@forcastortho.com
 303-503-4818 www.forcastortho.com



This Executive Summary has been prepared by ForCast Orthopedics Inc. (the “Company”) for investors, solely for informational purposes. The information contained herein has been prepared to assist prospective investors in making their own evaluation of the Company and does not purport to be all-inclusive or to contain all of the information a prospective or existing investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the Company and the data set forth in this information. The Company makes no representation or warranty as to the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information contained in, or for any omissions from, this information or any other written or oral communications transmitted to the recipient in the course of its evaluation of the Company. This information includes certain statements and estimates provided by the Company with respect to the projected future performance of the Company. Such statements, estimates and projections reflect various assumptions by management concerning possible anticipated results, which assumptions may or may not be correct. No representations are made as to the accuracy of such statements, estimates or projections. Prospective investors will be expected to have conducted their own due diligence investigation regarding these and all other matters pertinent to investment in the Company. These materials may contain statements that are not historical facts, referred to as “forward looking statements.” The Company’s actual future results may differ materially from those suggested by such statements, depending on various factors.

ForCast Orthopedics and the AD Knee Spacer have not yet been reviewed or cleared by the Food and Drug Administration for use in the United States. It is not currently available for sale.